NATUREX : Number of shares and voting rights as at April 30th, 2012

le
0

Article L.233-8-II of Commercial Law (Code de commerce) and
Article 223-16 of the General Regulation of the French Financial Markets Authority
(AMF - Autorité des Marchés Financiers)

Press release
Avignon, May 4th, 2012

30.04.2012

Total number of outstanding shares forming the capital
6,953,768 ordinary shares under ISIN FR0000054694   757,308 preferred shares under ISIN FR0010833251
7,711,076
Total number of outstanding shares forming the capital with voting rights
6,953,768 ordinary shares under ISIN FR0000054694
6,953,768
    Number of shares with double voting rights 212,340
Total number of gross voting rights 7,166,108
Number of shares without voting rights
6,543 bearer shares in the frame of the liquidity contract


- 6,543
Total number of exercisable voting rights* 7,159,565

*Real number of voting rights = total number of voting rights - number of shares without voting rights

If you would like to receive financial information about Naturex by e-mail, go to: www.naturex.com

Naturex has been listed since October 1996 on NYSE Euronext Paris, Compartment B (MidCaps)

Number of shares comprising the capital: 7,711,076 6,953,768 ordinary shares (ISIN FR0000054694)    757,308 preferred shares (ISIN FR0010833251) Naturex is a component of the CAC Small and Gaïa indexes.
Naturex is eligible for "long only" Deferred Settlement Service (SRD).
Naturex has implemented a Sponsored Level I American Depositary Receipt (ADR) program,
which trades on over-the-counter market in the United States under symbol NTUXY.

TICKER: NRX - Reuters : NATU.PA - Bloomberg : NRX:FP - DR Symbol: NTUXY

About Naturex
NATUREX is a global leader in specialty plant-based natural ingredients.
The Group is organised around three strategic markets (food & beverage, nutrition & health and personal care) and produces and markets specialty plant-based ingredients for the food, nutraceutical, pharmaceutical and cosmetic industries.
NATUREX's head office is based in Avignon, France. The company employs more than 1,000 people with high-performance manufacturing operations across 15 sites in Europe (France, Italy, Spain, the United Kingdom, Switzerland, Poland), as well as in Morocco, the United States, Brazil, Australia and India. It also has a global presence through a dedicated network of sales offices in 21 countries (France, Italy, Spain, Morocco, the United Kingdom, Belgium, Germany, Poland, Russia, U.A.E., Thailand, Singapore, Japan, China, Korea, Australia, the United States, Canada, Brazil, Mexico and India).
NATUREX's development is supported by positive underlying trends linked to a fast-growing demand for natural products and its capacity to provide manufacturers customised solutions to meet the requirements of their end consumers. The Group's strength lies in its positioning with specific products which constitute niche markets, supported by strong sourcing capacity and sustained research & development.

> Contacts
 
Jacques Dikansky
President and Chief Executive Officer
Tel.: +33 (0)4 90 23 96 89
naturex@naturex.com
 
Thierry Lambert
Vice-President and Chief Financial Officer
Tel.: +33 (0)4 90 23 96 89
t.lambert@naturex.com
 
Carole Alexandre
Investor Relations
Tel.: +33 (0)4 90 23 78 28
c.alexandre@naturex.com

Anne Catherine Bonjour
Actus Finance Press Relations
Tel.: +33 (0)1 53 67 36 93
acbonjour@actus.fr
Information réglementée
Information relative au nombre total de droits de vote et d'actions composant le capital :
- Communiqué intégral et original au format PDF :
http://www.actusnews.com/documents_communiques/ACTUS-0-27751-2012.05.04-nb-of-shares-and-voting-rights-30-april-2012.pdf © Copyright Actusnews Wire
Recevez gratuitement par email les prochains communiqués de la société en vous inscrivant sur www.actusnews.com
Receive by email the next press releases of the company by registering on www.actusnews.com, it's free

Valeur associée
  Libellé Bourse Dernier Var. Vol.
Vous devez être membre pour ajouter des commentaires.
Devenez membre, ou connectez-vous.
Aucun commentaire n'est disponible pour l'instant